Recently, mass spectrometry–based phosphoproteomics analyzed altered signaling networks in response to targeted radioligand therapy with 177Lu- and 255Ac-labeled PSMA in a prostate cancer mouse model (18). This evidence concerns the gene FOLH1 and prostate cancer.